

TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. Tel: 040 24757370, 29882220 Email: info@trimurthiltd.com

Website: www.trimurthiltd.com CIN No: L67120TG1994PLC018956

Date: 29.04.2023

To,
BSE Limited
P. J. Towers, Dalal Street,
Mumbai – 400001

Dear Sir/Madam,

Sub: Outcome of board meeting held on 29.04.2023

Unit: Trimurthi Limited (Scrip Code: 536565)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Trimurthi Limited held on Saturday, the 29<sup>th</sup> day of April, 2023 at p.m. at the registered office of the Company, the following were considered and approved by the Board:

- Audited financial results for the quarter and year ended 31.03.2023.
- Audit Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2023.

The meeting concluded at 5.00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,

For Trimurthi Limited

Arun Kumar Bhangadia

Henn Kas

Chairman & Managing Director

(DIN: 00021024)

Encl. as above



-3-354/1100, Common No. 1106,
Ratna Bleck, Fire the Patha Towers,
Id.
Hyderab - 1, Idlandana - 500 001.

### TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. Tel: 040 24757370, 29882220 Email: info@trimurthiltd.com

Website: www.trimurthiltd.com
CIN No: L67120TG1994PLC018956

Date: 29.04.2023

To.

BSE Limited P.J. Towers, Dalal Street, Mumbai-400 001

Dear Sir/Madam,

Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, Arun Kumar Bhangadia, Chairman & Managing Director of Trimurthi Limited hereby declare that the statutory Auditors of the company, M/s. P. Murali & Co., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31<sup>st</sup> March, 2023.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Yours sincerely,

For Trimurthi Limited

Arun Kumar Bhangadia

Chairman & Managing Director

(DIN: 00021024)



(ii) DILUTED

TRIMULES Se No. 1106,
5-8-354/110 Se No. 1106,
Ratna Block Se Ratna Towers,
Chine Lead, Abid,
Chine Lead, Telangena - 500 001.

## TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. Tel: 040 24757370, 29882220 Email: info@trimurthiltd.com

Email: info@trimurthiltd.com Website: www.trimurthiltd.com CIN No: L67120TG1994PLC018956

#### TRIMURTHI LIMITED

Regd Off: 5-8-354/1106, Office No. 1106, Ratna Block, Raghav Ratna Towers, Chirag Ali Lane, Hyderabad, Telangana – 500001; STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER IV AND YEAR ENDED 31ST MARCH 2023

(Amount in Lakhs Except EPS) QUARTER ENDED YEAR ENDED PARTICULARS 31.03.2023 31.03.2022 31.03.2022 31.12.2022 31.03.2023 (AUDITED) (AUDITED) (UNAUDITED) (AUDITED) (AUDITED) 1. INCOME 42.64 7.13 140 46 84 32 INCOME FROM OPERATIONS 23.25 18.2 51.57 55.17 OTHER INCOME 139.49 109.83 60.91 16.25 192.03 TOTAL INCOME 2. EXPENSES 92.67 64.52 3.59 164.09 109.19 PURCHASES COST OF MATERIALS CONSUMED MANUFACTURING EXPENSES (28.37) (24.74) 5.44 (28.86) (4.67 INCREASE/(DECREASE) IN STOCK IN TRADE 0.30 1.30 1.50 2.10 0.30 RENT 9.49 31.18 29.10 10.47 6.87 EMPLOYEE BENEFITS EXPENSE FINANCE COSTS 7.16 1.41 2 47 1.68 5.62 DEPRECIATION AND AMORTISATION EXPENSES 176.88 157.57 24.36 OTHER EXPENSES 4.96 197.88 296.07 54.38 179.07 108.41 TOTAL EXPENSES 3. PROFIT/(LOSS) FROM BEFORE EXCEPTIONAL ITEMS AND TAX (1-2) (162.82 (5.85 (156.58 1.42 4 EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS (156.58)(162.82) (5.85 6.53 5. PROFIT/(LOSS) FROM CONTINUING OPERATIONS BEFORE TAX (3-4) 1.42 (0.55)(0.04)0.24 0.03 (0.15) 6. TAX EXPENSES -CURRENT TAX -TAX ADJUSTMENTS RELATING TO EARLIER YEARS (0.55)0.24 (0.15 (0.04)-DEFERRED TAX (NET) 6.76 (162.75 (5.99 (156.03)7. NET PROFIT/(LOSS) FROM CONTINUING OPERATIONS AFTER TAX (5-6) 8.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS 9.TAX EXPENSES FOR DISCONTINUED OPERATIONS 10.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-(162.75) (5.99) (156.03) 6.76 11.PROFIT/(LOSS) FOR THE PERIOD (7+10) 1.38 12.OTHER COMPREHENSIVE INCOME 1.20 A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS (ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS (ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS 13.TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME) (156.03) (162.75)(4.79) 6.76 2.58 14.EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION): 0.02 0.08 (2.01)(0.07)(1.93)(i) BASIC (2.01 (0.07)(1.93)0.02 0.08 (ii) DILUTED 15.EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION): (i) BASIC (ii) DILUTED 16.EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION) (i) BASIC 0.02 0.08 (2.01)(0.07



(2.01)

(0.07

(1.93)



5-8-354/1106, Office No. 1106, Ratna Block, Ragnay Ratna Towers, Chirag A TRIMURTHI LIMITED.

TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. Tel: 040 24757370, 29882220

Email: info@trimurthiltd.com

|    | GROUP PARTICULARY derabad, Teland   | ana - aud du Quarter ended Wedsite : WWW.Itimuryearenden |                           |                         |                         |                                   |  |
|----|---|--|---------------------------|-------------------------|-------------------------|-----------------------------------|--|
|    |   | 31.03.2023<br>(AUDITED)                                  | 31.12.2022<br>(UNAUDITED) | 31.03.2022<br>(AUDITED) | 31.03.2023<br>(AUDITED) | 018956<br>31.03.2022<br>(AUDITED) |  |
| A. | PARTICULARS OF SHARE HOLDING  |  |                           |                         |                         |                                   |  |
| I. | Public Share Holding  |  |                           |                         |                         |                                   |  |
|    | - Number of Shares  | 2679267  | 2679267                   | 2900600                 | 2679267                 | 2900600                           |  |
|    | - Percentage of shareholding  | 33.08%   | 33.08%                    | 35.81%                  | 33.08%                  |                                   |  |
|    | Promoters and promoter group shareholding                                   | 5,5100.18  | 0.0.0076                  | 33.0170                 | 33.08%                  | 35.81%                            |  |
|    | a. Pledged / encumbured   |  |                           |                         |                         |                                   |  |
|    | - No of Equity Shares   | -Nil-  | -Nil-                     | -Nil-                   | -Nil-                   | -Nil-                             |  |
|    | - Percentage of Shares (of the shareholding of promoter and promoter group) | -Nil-  | -Nil-                     | -Nil-                   | -Nil-                   | -Nil-                             |  |
|    | - Percentage of Shares (of the total share capital of the company)          | -Nil-  | -Nil-                     | -Nil-                   | -Nil-                   | -Nil-                             |  |
|    | b. Non encumbured   |  |                           | -1411-                  | SINIIS                  | -1711-                            |  |
|    | - No of Equity Shares   | 5420733  | 5420733                   | 5199400                 | 5420733                 | 5199400                           |  |
|    | - Percentage of Shares (of the shareholding of promoter and promoter group) | 100.00%  | 100.00%                   | 100.00%                 | 100.00%                 | 100,00%                           |  |
|    | - Percentage of Shares (of the total share capital of the company)          | 66.92%   | 66.92%                    | 64.19%                  | 66.92%                  | 64.19%                            |  |

|    | Particulars                             | 3 Months Ended ( 31/03/2023) |
|----|---|------------------------------|
| В. | Investor Complaints                     | 5 Months Emilia ( 54 04 2025 |
|    | Pending at the beginning of the quarter | -NIL-                        |
|    | Received during the quarter             | -NIL:                        |
|    | Disposed during the quarter             | -NIL-                        |
|    | Remaining unsolved during the quarter   | -NIL-                        |

#### TRIMURTHI LIMITED

#### Segment Reporting

|          | PARTICULARS  | 31.03.2023 | QUARTER ENDED             |                         | YEAR E                  | NDED                    |
|----------|--|------------|---------------------------|-------------------------|-------------------------|-------------------------|
|          | PARTICULARS  |            |                           |                         |                         |                         |
|          |  | (AUDITED)  | 31.12.2022<br>(UNAUDITED) | 31.03.2022<br>(AUDITED) | 31.03.2023<br>(AUDITED) | 31.03.2022<br>(AUDITED) |
|          | Segment Revenue  |            |                           |                         | 11. 1                   |                         |
|          | a. Pharma Business   | 14.59      | 4.08                      | 8.70                    | 21.22                   |                         |
|          | b. Financial Services                                      | 10.04      | 7.20                      |                         | 21.32                   | 8.70                    |
|          | c. Investments   | 13.21      | 11.07                     | 9.11                    | 27.27                   | 29,78                   |
| _        | d. Trading in Shares                                       | 71.99      | 38.56                     | (24.99)                 | 24.30                   | 0.39                    |
| Total    | e. Foods   | 71,99      |                           | 23.44                   | 119.14                  | 100.62                  |
|          |  | 109.83     | 60.91                     |                         |                         | -                       |
| Less: In | iter Segment Revenue                                       | 107.03     | 60.91                     | 16.25                   | 192.03                  | 139,49                  |
|          | es/ Income From Operations                                 | 109.83     | 60.91                     | 16.25                   | 192.03                  | 440.40                  |
| 2.       | Segment Profits ( Before tax & Interest From Each Segment) | 100,00     | 00.51                     | 10.23                   | 192.03                  | 139,49                  |
|          | a. Pharma Business   | 5.29       | -2.01                     |                         |                         |                         |
|          | b. Financial Services                                      | 10.04      | 7.20                      | 10.70                   | 4.83                    |                         |
| ,        | c. Investments   | 13.21      | 11.07                     | (5.62)                  | 27.27                   | 15.05                   |
|          | d. Trading in Shares                                       | (27.13)    | -9.73                     | (174.92)                | 24.30                   | (149.54                 |
|          | e. Foods   | (27:13)    | -9.73                     | 17,73                   | (62.25)                 | (22.09                  |
| Total    |  | 1.42       | 6,53                      | (162.81)                | (5,85)                  | (45.50                  |
| less:    |  |            | 0.00                      | (102.01)                | (5.65)                  | (156.58                 |
|          | i. Interest  |            |                           |                         |                         |                         |
|          | ii. Other Un-allocable expenses net off                    |            |                           |                         |                         |                         |
|          | iii. Un-allocable Income                                   |            |                           |                         |                         |                         |
|          | Total Profit Before Tax                                    | 1.42       | 6.53                      | (2.50.04)               | (0.00)                  |                         |
| 3, (     | Capital Employed   | 1.42       | 0.33                      | (162.81)                | (5.85)                  | (156.58                 |
| - 1      | a. Pharma Business   | 55.82      | 40.18                     |                         |                         |                         |
| 1        | p. Financial Services                                      | 7.78       |                           | 29.50                   | 55.82                   | 29.50                   |
| 1        | Investments  | 277.52     | 104.82                    | 301.63                  | 7.78                    | 301.63                  |
| (        | f. Trading in Shares                                       | 378.39     | 203.20                    | 43.92                   | 277.52                  | 43.92                   |
|          | e. Foods   | 3/8.39     | 368.75                    | 349.25                  | 378.39                  | 349.25                  |
|          | Total  | 719.51     | 716.95                    | 724.30                  | 719.51                  | 724.30                  |

#### Notes

- Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- The Audited Financial Results for the year ended 31st March, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29th April, 2023. The Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.
- The above financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.
- 4 The results are also available on the webiste of the Company.
- During the year company has sold its 100% equity shares of Trimurthi Pharmaceuticals (India) Private Limited, Subsidiary Company, as such it ceased to be the Subsidiary of Trimurthi limited. The company has obtained the necessary consent from shareholders and complied the provisions of the Companies Act, 2013.
- During the Quarter company has sold its investment in M/s. Curova India LLP, an associate enterprise, as such it ceased to be the associate of Trimurthi limited. The company has obtained the necessary consent from shareholders and complied the provisions of the companies Act, 2013.
- The figures of last quarter are the balancing figures between the audited figures in respect of the full financial year upto 31st March 2023 and the unaudited published year to date figures upto 31st December 2022, being the date of the end of the third quarter of the financial year which were subjected to limited review.

Place: Hyderabad Date: 29-04-2023.





TREMITEDERI E.I.M. 1 18.10 5-8-354/1105, Office No. 1106, Ratna Block, Raghav Ratna Towers, Chron Ali Lane, Abid, Hyderabad, Telaugana - 500 001.

# TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. Tel: 040 24757370, 29882220 Email: info@trimurthiltd.com

Website: www.trimurthiltd.com
CIN No: L67120TG1994PLC018956

| TRIMURTHI LIMITED  Regd Off: 5-8-354/1106, Office No. 1106, Ratna Block, Raghav Ratna Towers, Chirag Ali Lane, Hyderabad, Telangana - 500001;   |   |                          |  |                        |  |  |
|---|---|--------------------------|--|------------------------|--|--|
| STANDALONE BALANCE SHEET AS AT 31-03-2023   |   |                          |  |                        |  |  |
| PARTICULARS   |   | Figures as at 31/03/2023 |  | as at<br>2022          |  |  |
| ASSETS:   |   |                          |  |                        |  |  |
| A. Non Current Assets  (a) Property, Plant and Equipment  (b) Capital Work In Progress  (c) Investment Property  (d) Other Intangible Assets  (e) Financial Assets  (i) Investments  (ii) Trade Receivables   | 1,741.89<br>-<br>0.10<br>27,751.87                      |                          | 2,260.28<br>17,387.96<br>0.10<br>5,882.00                |                        |  |  |
| (iii) Loans (iv) Other Financial Assets (f) Deferred Tax Assets (Net) (g) Other Non Current Assets  | 646.45  | 30,140.31                | 660.98   | 26,191.33              |  |  |
| B. Current Assets  (a) Inventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash & Cash Equivalents (iv) Bank Balances other than (iii) above (v) Short Term Loans and Advances (vi) Others  | 8,205.61<br>1,904.58<br>27,747.44<br>777.84<br>3,791.77 |                          | 5,319.14<br>998.02<br>26,049.22<br>10,917.54<br>3,036.81 |                        |  |  |
| TOTAL ASSETS  |   | 42,427.23<br>72,567.54   |  | 46,320.72<br>72,512.05 |  |  |
| A. Equity (a) Equity Share Capital (b) Other Equity  . Non Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade Payables (iii) Other Financial Liabilities (b) Provisions (c) Deferred To Liabilities (b)  | 81,000.00<br>(9,048.88)                                 | 71,951.12                | 81,000.00<br>(8,569.45)                                  | 72,430.55              |  |  |
| (c) Deferred Tax Liabilities (Net) (d) Other Non Current Liabilities  Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Trade Payables (iii) Other Financial Liabilities (b) Other Current Liabilities (c) Provisions (d) Current Tax Liabilities (Net) | 537.97<br>78.45   | 616.42                   | 81.50  |                        |  |  |
| TOTAL EQUITY AND LIABILITIES  |   | 72,567.54                |  | 81.50<br>72,512.05     |  |  |





TRIMEDE LEMIT 1850 5-8-354/1103, Office No. 1106, Ratna Block, Farmay Ratna Towers, Ching fill Lone, Abid, Hyderabad, Telengana - 500 001.

## TRIMURTHI LIMITED

4-4-231/1/2/ABC, Inderbagh, Sultanbazar, Hyderabad - 500 095, T.S. INDIA. Tel: 040 24757370, 29882220

Email: info@trimurthiltd.com Website: www.trimurthiltd.com CIN No: L67120TG1994PLC018956

#### TRIMURTHI LIMITED

Regd Off: 5-8-354/1106, Office No. 1106, Ratna Block, Raghav Ratna Towers, Chirag Ali Lane, Hyderabad, Telangana – 500001

### STANDALONE CASH FLOW STATEMENT FOR THE PERIOD ENDED 31st MAR 2023

| Particulars                                       | As at 31-03-2023 | As at 31-03-2022 |
|---|------------------|------------------|
| A. Cash Flow from Operating Activities:           |                  |                  |
| Net Profit before Tax and Extraordinary Items     | (584.76)         | (15,657,98       |
| Adjustments for:                                  |                  |                  |
| Depreciation                                      | 562.18           | 716.37           |
| Interest & Other Income                           | (5,157.32)       | (5,516.92        |
| Loss on Sale of Fixed Assets                      | 1                | 225.83           |
| Loss on Sale of Investments & Property            |                  | 15,003.00        |
| Profit on sale of mutual funds                    |                  | (35.16           |
| Operating profit before Working Capital Changes   | (5,179.91)       | (5,264.85        |
| Adjustments for:                                  | 1272 87          | 2007             |
| Trade and Other receivables                       | 8,478.17         | 14,191.57        |
| Inventories                                       | (2.886.47)       | (2,837.22        |
| Trade & Other payables                            | 534.92           | (159.87          |
| Cash generated from Operations                    | 6,126.62         | 11,194,49        |
| Cash flow before Extraordinary Items              | 946.71           | 5,929.64         |
| Extraordinary Items and Tax                       |                  | 10               |
| Net Cash used for Operating activities            | 946.71           | 5,929.64         |
| 3. Cash Flow from Investing Activities:           |                  |                  |
| Purchase of Fixed Assets                          | (43.79)          | (18,647.83       |
| Sale of Fixed Assets                              | (100.3)          | 300.00           |
| Capital Work in progress                          |                  | ,500.00          |
| Sale of Investments                               | 22,837.96        | 15,582.16        |
| Increase / (Decrease) in Security Deposits        | (27,200.00)      | 10,002.10        |
| Interest & Other Income                           | 5,157.32         | 5,516.92         |
| Net Cash flow from Investing activities           | 751.50           | 2,751.25         |
| C. Cash Flow from Financing Activities:           |                  |                  |
| Increase in Share Capital                         |                  |                  |
| Increase in Share Premium                         |                  |                  |
| Increase / Decrease in Long Term Borrowings       |                  |                  |
| Share Issue and Preliminary Expenses              |                  |                  |
| Dividends Paid                                    |                  |                  |
| Net Cash flow from Financing activities           |                  |                  |
| Net Increase in Cash and Cash Equivalents         | 1.698.21         | 8,680.89         |
| Cash and Cash Equivalents as at (Opening Balance) | 26.049.23        | 17,368.34        |
| Cash and Cash Equivalents as at (Closing Balance) | 27,747.44        | 26,049.23        |





Tel. : (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470

FAX : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com

info@pmurali.com Website:www.pmurali.com

#### INDEPENDENT AUDITOR'S REPORT

TO
THE BOARD OF DIRECTORS OF
TRIMURTHI LIMITED

Report on the audit of the Ind AS Financial Results

## Opinion:

We have audited the accompanying Ind AS quarterly financial results of M/s. Trimurthi Limited for the quarter ended 31st March, 2023 and the year to date results for the period from 01-04-2022 TO 31-03-2023, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").


In our opinion and to the best of our information and according to the explanations given to us these financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net loss and other comprehensive income and other financial information for the quarter ended 31st March, 2023 as well as the year to date results for the period from 01-04-2022 to 31-03-2023.

### Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.





Tel. : (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470

FAX : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com

info@pmurali.com Website : www.pmurali.com

# Emphasis of Matter Paragraph:

a) As disclosed in Note 5 to the Financial Results, during the financial year 2022-23, the company has sold its Subsidiary company, Trimurthi Pharmaceuticals (India) Private Limited.

b) As disclosed in Note 6 to the Financial Results, during the quarter under audit, the company has sold its Associate Enterprise, Curova India LLP.


Our Opinion is not modified in respect of the above matter.

# Management's Responsibilities for the Financial Results

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.



Tel. : (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470

FAX : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com info@pmurali.com

Website : www.pmurali.com


## Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results,
  whether due to fraud or error, design and perform audit procedures responsive
  to those risks, and obtain audit evidence that is sufficient and appropriate to
  provide a basis for our opinion. The risk of not detecting a material
  misstatement resulting from fraud is higher than for one resulting from error, as
  fraud may involve collusion, forgery, intentional omissions, misrepresentations,
  or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in
  order to design audit Procedures that is appropriate in the circumstances.
  Under section 143(3)(i) of the Act, we are also responsible for expressing our
  opinion on whether the Company has adequate internal financial controls
  system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness
  of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Hyderabad



Tel. : (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470

FAX : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com info@pmurali.com

Website: www.pmurali.com

 Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The Financial Results include the results for the quarter ended 31st March 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For P. Murali& Co,

Chartered Accountants, FRN No: 007257S

A. Krishna Rao

Partner

M.No:020085 UDIN: 23020085 BGOXEN4063

Hyderabad

Place: Hyderabad Date: 29-04-2023